Evidence of reduced ADAMTS13 activity in the presence of schistocytes (~ 2–4%) appeared compatible with thrombotic microangiopathy (TMA) secondary to COVID-19 [34]. The gene discussed is ADAMTS13; the disease is Genetic thrombotic microangiopathy.